background  aims curcumin is a biologically active phytochemical substance present in turmeric and has pharmacologic actions that might benefit patients with ulcerative colitis ucthe aim in this trial was to assess the efficacy of curcumin as maintenance therapy in patients with quiescent ulcerative colitis ucmethods eightynine patients with quiescent uc were recruited for this randomized doubleblind multicenter trial of curcumin in the prevention of relapsefortyfive patients received curcumin 1g after breakfast and 1g after the evening meal plus sulfasalazine sz or mesalamine and 44 patients received placebo plus sz or mesalamine for 6 monthsclinical activity index cai and endoscopic index ei were determined at entry every 2 months cai at the conclusion of 6month trial and at the end of 6month followupresults seven patients were protocol violatorsof 43 patients who received curcumin 2 relapsed during 6 months of therapy 465 whereas 8 of 39 patients 2051 in the placebo group relapsed p040recurrence rates evaluated on the basis of intention to treat showed significant difference between curcumin and placebo p049furthermore curcumin improved both cai p038 and ei p0001 thus suppressing the morbidity associated with uca 6month followup was done during which patients in both groups were on sz or mesalamineeight additional patients in the curcumin group and 6 patients in the placebo group relapsedconclusions curcumin seems to be a promising and safe medication for maintaining remission in patients with quiescent ucfurther studies on curcumin should strengthen our findings